Champions Oncology, Inc. (CSBR) Q2 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights several positives: revenue growth, margin expansion, and a strong cash position. Gross margins improved significantly, and the company anticipates further expansion. Although operating expenses increased due to strategic investments, the funding environment is improving, and cancellations have returned to historic levels. The Q&A session revealed optimism about market recovery and strategic hires to boost the data business. Despite some uncertainties, the overall sentiment is positive, with expectations of continued growth and profitability, likely resulting in a stock price increase of 2% to 8%.
Key Financial Performance
Total Revenue $15 million for the quarter, compared to $13.5 million last year, an increase of 11% year-over-year. The increase was driven by improved conversion of booked work due to a lower level of cancellations.
Income from Operations $185,000 for the quarter. No year-over-year comparison or reasons for change were provided.
Adjusted EBITDA Approximately $800,000 for the quarter. No year-over-year comparison or reasons for change were provided.
Gross Margin 52% for the quarter, compared to 45% last year. The improvement was due to flat cost of sales ($7.3 million this quarter compared to $7.4 million last year) on an increased revenue base.
Operating Expenses $7 million for the quarter, up about $2 million from last year. The increase was driven by investments in the data platform, including $900,000 in R&D for sequencing and related costs, $200,000 for Corellia's target discovery initiatives, and $800,000 in G&A for leadership transitions and IT infrastructure investments.
Net Cash Used in Operating Activities $1.9 million for the quarter. The primary driver was a decrease in deferred revenue as revenue was recognized on cash received in advance.
Cash Position $8.5 million at the end of the quarter, with no debt. No year-over-year comparison or reasons for change were provided.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Radiolabeling and radiopharmaceutical support workflows: Champions operates one of the few labs approved for specialized radiolabeling work, a growing area in oncology drug development. This capability is expected to become a significant part of their service offering, improving gross margins as reliance on outsourced services decreases.
Data platform enhancements: Investments are being made to enhance the functionality and utility of the data platform for pharma partners. This platform combines biological data, pharmacology capabilities, and PDX assets, supporting target identification, validation, and translational insights.
Customer engagement and pipeline generation: Gradual improvement in pharma and biotech budgets has led to increased customer engagement and opportunity pipeline generation. Optimism exists for booking momentum in calendar 2026.
Revenue growth and margin improvement: Revenue increased by 11% year-over-year to $15 million, driven by improved conversion of booked work and reduced cancellations. Gross margin improved to 52% from 45% last year.
Operational efficiencies: Operational efficiencies contributed to margin improvement, with flat cost of sales on an increased revenue base.
Corellia subsidiary funding: Discussions with venture capital funding partners for Corellia are progressing. Once funding is secured, investments will be redirected to accelerate growth in the data business.
Investments in commercial and business development teams: Targeted investments are being made to support anticipated growth in radiolabeling and data platform offerings, increasing near-term OpEx but aligning with long-term strategy.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Pharma and Biotech Budget Constraints: Funding levels in the pharma and biotech sectors have not fully recovered, which could impact customer engagement and pipeline generation.
Operational Efficiency: The company is focused on improving operational efficiency, but any failure in execution could adversely affect margins and revenue growth.
Reliance on Outsourced Services: The company is working to bring more radiolabeling work in-house to improve margins, but current reliance on outsourced services could pose a risk to cost control.
Increased Operating Expenses: Investments in data platforms and commercial teams have increased operating expenses, which could pressure short-term financial performance.
Corellia Subsidiary Funding: The subsidiary Corellia is still seeking venture capital funding, and until secured, it will continue to impact the company's P&L.
Market Conditions: Gradual improvement in market conditions is noted, but uncertainties remain, particularly in R&D budget resets for 2026.
Temporary G&A Increases: General and administrative expenses have risen due to leadership transitions and IT infrastructure investments, which may temporarily strain financials.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects to deliver year-over-year revenue growth for fiscal 2026, supported by improved market conditions and increased customer engagement.
Adjusted EBITDA: The company aims to achieve full-year positive adjusted EBITDA for fiscal 2026, maintaining fiscal discipline and self-funding growth without shareholder dilution.
Market Trends: Gradual improvement in pharma and biotech budgets is expected, with cautious optimism for booking momentum as R&D budgets reset for calendar 2026.
Radiolabeling and Radiopharmaceuticals: The company anticipates increased demand for its radiolabeling services, positioning this segment as a significant part of its service offering over time. Bringing more work in-house is expected to improve gross margins.
Data Platform Investments: Continued investment in the data platform is expected to enhance functionality and expand utility for pharma partners, driving long-term value and revenue growth.
Corellia Subsidiary: The company is in discussions with venture capital funding partners for Corellia, with plans to redirect investment dollars toward accelerating growth in the data business once external funding is secured.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Have cancellations returned to historic levels, and how is the funding environment impacting inbound call volume and revenue growth?
A:Cancellations have returned to historic levels, and the funding environment is improving. The company is optimistic about opportunity generation despite a tough market. A survey of 77 biotech executives showed over one-third planning to increase outsourcing next year, with less than 2% forecasting a decline. Investments in the commercial team position the company well for market recovery.
Q:Are the new sales and marketing hires exclusively targeting the data opportunity, or are they also supporting other services?
A:Some hires are supporting both the data opportunity and other services. A notable hire is Dr. Tammer Farid, who will lead the data business as General Manager. He brings strategic and domain expertise to enhance discovery and development programs. The company is committed to investing in this area despite ongoing work.
Q:What is the outlook for gross margins for the remainder of the year, and what factors could impact them?
A:Gross margins for the service business are expected to remain in the 50%-52% range or slightly higher. Factors like outsourced lab service costs (e.g., radiolabeling) during the transition to in-house work and revenue fluctuations could impact margins. The company anticipates an overall lift to margins as they expand into data.
Q:How far along are the drug candidates for Corellia, and what valuation range is being considered?
A:The company has not publicly shared details about Corellia's drug candidates or valuation range. They are excited about the data and traction with VC partners but did not provide specific information, stating they will share updates when more meaningful details are available.
Q:Review of Unclear Management Responses
A:The company avoided providing specific details about Corellia's drug candidates and valuation range, citing that they have not shared this information publicly. They only mentioned being excited about the data and traction with VC partners, leaving the question largely unanswered.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CFO today
Champions advantage
Champions investment
Champions lab
Champions market
Corellia PL
Corellia subsidiary
Customer interest
Funding level
PDX asset
PL case
PL focus
SEC core
TOS lever
action position
advantage progress
advantage tumor
afternoon today
area Champions
area advantage
area interest
asset platform
bank capability
base customer
biopharma relationship
booking efficiency
budget Funding
budget calendar
calendar context
calendar momentum
cancellation margin
capability Champions
capability PDX
focus conversion
funding
goal
leverage
offering
radiolabeling
work
CSBR Transcript
Champions Oncology, Inc. (CSBR) Q3 2026 Earnings Call Transcript
Unknown3-12
The earnings call presents mixed signals: a decline in year-over-year revenue and gross margins, and increased operating expenses, are concerning. However, positive adjusted EBITDA, growth in core study revenue, and strategic investments in data and radiopharmaceuticals offer optimism. The absence of Q&A questions limits further sentiment insight. Given these mixed factors, the stock price is likely to remain stable over the next two weeks.
Champions Oncology, Inc. (CSBR) Q2 2026 Earnings Call Transcript
Positive12-15
The earnings call highlights several positives: revenue growth, margin expansion, and a strong cash position. Gross margins improved significantly, and the company anticipates further expansion. Although operating expenses increased due to strategic investments, the funding environment is improving, and cancellations have returned to historic levels. The Q&A session revealed optimism about market recovery and strategic hires to boost the data business. Despite some uncertainties, the overall sentiment is positive, with expectations of continued growth and profitability, likely resulting in a stock price increase of 2% to 8%.
Champions Oncology, Inc. (CSBR) Q1 2026 Earnings Call Transcript
Unknown9-15
The earnings call reveals mixed signals: stable revenue with signs of recovery but increased costs leading to a loss. The data business shows potential growth, but management's vague responses in the Q&A about future opportunities and revenue guidance create uncertainty. Operational inefficiencies and increased expenses further complicate the outlook. Despite optimism in some areas, the lack of clear guidance and current financial strain suggest a neutral stock movement in the short term.
Champions Oncology (CSBR) Q4 2025 Earnings Call Transcript
Unknown7-25
The earnings call presents mixed signals. Financial performance shows positive trends with increased annual revenue and improved EBITDA, but quarterly metrics are weak, with declining Q4 revenue and margins. Product development shows promise in high-margin areas like radiopharmaceuticals, yet the Q&A reveals uncertainties in data licensing and partnerships. The company's cautious optimism about fiscal '26 and improved cash position are positives, but lack of specific guidance and rising expenses temper enthusiasm. Overall, the mixed financials and unclear growth prospects suggest a neutral short-term stock price reaction.
CSBR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
